DPP4 and Hypoglycemia: Compared with placebo or no treatment, DPP-4 inhibitor therapy did not increase the incidence of hypoglycemia (1,049 participants, random RR 1.10, 95%CI 0.92 to 1.32; p = 0.30) (Figure 8A), and there was no heterogeneity (I2 = 0%; p = 0.43).